Search

agbiopro
- Jun 30, 2020
- 0 min read

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

Recent Posts

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation